Intercept Pharmaceuticals Company Profile (NASDAQ:ICPT)

Intercept Pharmaceuticals trades on the NASDAQ under the ticker symbol "ICPT."

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) announced its earnings results on Thursday, May, 4th. The company reported ($3.61) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($4.27) by $0.66. The company had revenue of $21 million for the quarter, compared to analysts' expectations of $15.88 million. Intercept Pharmaceuticals had a negative net margin of 825.58% and a negative return on equity of 116.30%. The business's revenue for the quarter was up 4566.7% on a year-over-year basis. During the same period last year, the firm earned ($5.17) earnings per share. View Intercept Pharmaceuticals' Earnings History.

16 analysts have issued twelve-month price objectives for Intercept Pharmaceuticals' stock. Their predictions range from $60.00 to $350.00. On average, they expect Intercept Pharmaceuticals' stock price to reach $203.00 in the next twelve months. View Analyst Ratings for Intercept Pharmaceuticals.

Here are some recent quotes from research analysts about Intercept Pharmaceuticals stock:

• 1. According to Zacks Investment Research, "Intercept received a boost with the approval of Ocaliva in 2016 and the initial uptake of the same has been encouraging. The drug’s sale is expected to pick up further in 2017. The PBC market holds strong potential.  We are also encouraged by Intercept’s efforts to develop the drug for additional indications. A potential label expansion of the drug will further boost sales. The company does not expect much contribution from international markets in 2017 and most of it will be loaded in the second half as it works to obtain reimbursements in various European countries. However, expenses are expected to continue to rise as the company invests in commercial activities related to Ocaliva. We also remain concerned about the lack of other late-stage candidates in Intercept’s pipeline.  Moreover, the company’s share underperformed the industry in the last one year." (7/11/2017)
• 2. Cowen and Company analysts commented, "We hosted a group investor lunch recently with ICPT management." (6/12/2017)
• 3. BMO Capital Markets analysts commented, "We are raising our PT to $221 from $198 as we believe updated launch metrics suggest continued steady uptake of Ocaliva for PBC driven by greater physician awareness and more open access, supporting our above-consensus 2017 sales estimates. We believe the removal of the REGENERATE enrollment overhang could allow ICPT shares to trade up meaningfully on any signs of efficacy in PSC Ph2 as it remains a source of upside to our and Street estimates. We expect Ocaliva sales growth and development milestones to help ICPT shares recover." (2/24/2017)
• 4. Wedbush analysts commented, "We believe several clinical catalysts later this year could provide upside to ICPT's current price. Q4/FY:16 Financials: Q4/FY:16 Ocaliva sales were $13.4MM/$18.2MM. Revenues of $13.8MM/$24.9MM also came in higher than consensus estimates of $8.96MM/$20.16MM. GAAP (loss) of $(4.84)/$16.74) came in lower than consensus estimates of $(3.68)/($15.63) on higher than expected SG&A expenses. We have incorporated Q4/FY:16 financials and updated our model based on 2017 guidance. ICPT ended 2016 with cash balance of $689.4MM. Progress on the Ocaliva launch. ICPT appears to be making significant progress with reimbursement, with the time to filled-prescription now at three weeks." (2/24/2017)
• 5. Needham & Company LLC analysts commented, "Intercept reported 4Q16 financial results today. Ocaliva sales were $13.4M, compared to our $9.0M and consensus $7.8M est. Mgmt cited better than expected gross:net. No sales guidance was issued, as expected, although mgmt indicated 1Q17 sales will only be modestly above 4Q16, w/ expectations for gross:net to worsen. As a reminder, drug was launched in Jun 2016 for treatment of PBC. Ocaliva launch is progressing well, but we believe this is already factored in stock. Mgmt recently negotiated changes to Phase 3 REGENERATE NASH trial design, allowing for smaller pt population. We expect a favorable outcome, but note results will still not be available until 1H19." (2/23/2017)

Some companies that are related to Intercept Pharmaceuticals include Kite Pharma (KITE), bluebird bio (BLUE), Neurocrine Biosciences (NBIX), Clovis Oncology (CLVS), Juno Therapeutics (JUNO), BeiGene (BGNE), Ultragenyx Pharmaceutical (RARE), GW Pharmaceuticals PLC (GWPH), China Biologic Products (CBPO), Agios Pharmaceuticals (AGIO), Prothena Corporation PLC (PRTA), Sarepta Therapeutics (SRPT), AveXis (AVXS), Axovant Sciences (AXON), Spark Therapeutics (ONCE), Loxo Oncology (LOXO), Aerie Pharmaceuticals (AERI) and Radius Health (RDUS).

Intercept Pharmaceuticals' management team includes the folowing people:

• Paolo Fundaro, Independent Chairman of the Board
• Mark Pruzanski M.D., President, Chief Executive Officer, Director
• Sandip S. Kapadia, Chief Financial Officer, Treasurer
• Lisa Bright, President, International
• Jerome Benedict Durso, Chief Operating Officer
• David Ford, Chief Human Resource Officer
• David M. Shapiro M.D., Chief Medical Officer, Executive Vice President - Development
• Richard Kim, Senior Vice President, Commercial U.S.
• Rachel L. McMinn Ph.D., Chief Business and Strategy Officer
• Srinivas Akkaraju M.D. Ph.D., Independent Director

Intercept Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include Bank of Montreal Can (0.10%), Fox Run Management L.L.C. (0.02%), Rothschild Investment Corp IL (0.02%), Creative Planning (0.01%) and Aperio Group LLC (0.01%). Company insiders that own Intercept Pharmaceuticals stock include Barbara Gayle Duncan, Daniel G Welch, David Shapiro, Klaus R Dr Veitinger, Lisa Bright, Mark Pruzanski, Nicole Williams, Rachel Mcminn, Richard J Kim and Sandip Kapadia. View Institutional Ownership Trends for Intercept Pharmaceuticals.

Intercept Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Creative Planning and Bank of Montreal Can. Company insiders that have sold Intercept Pharmaceuticals stock in the last year include Barbara Gayle Duncan, Daniel G Welch, David Shapiro, Lisa Bright, Mark Pruzanski, Rachel Mcminn, Richard J Kim and Sandip Kapadia. View Insider Buying and Selling for Intercept Pharmaceuticals.

Intercept Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Fox Run Management L.L.C. and Aperio Group LLC. View Insider Buying and Selling for Intercept Pharmaceuticals.

Shares of Intercept Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Intercept Pharmaceuticals stock can currently be purchased for approximately $127.40.